Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Berzosertib
Colorectal Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Berzosertib
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Berzosertib
Fallopian Tube Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Berzosertib
Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Breast Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Colorectal Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Nut Midline Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Endometrial Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Endometrial Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Ovarian Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Ovarian Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Ovarian Serous Adenocarcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Ovarian Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Bet Bromodomain Inhibitor Zen-3694
Colorectal Cancer
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Head And Neck Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Autoimmune Disease
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Bladder Transitional Cell Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Crohn Disease
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Dermatomyositis
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Inflammatory Bowel Disease
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Squamous Cell Carcinoma Of Penis
National Cancer Institute (NCI)
P1
CC
(43)
Cabozantinib
Psoriasis
National Cancer Institute (NCI)
P1
CC
(43)
Showing 2726 to 2750 of 3,272 assets
Previous
Page 110 of 131
Next